{"id":"https://openalex.org/W2188321475","doi":null,"title":"Novel Immunotherapy to Eliminate Minimal Residual Disease in AML","display_name":"Novel Immunotherapy to Eliminate Minimal Residual Disease in AML","publication_year":2013,"publication_date":"2013-01-01","ids":{"openalex":"https://openalex.org/W2188321475","mag":"2188321475"},"language":"en","primary_location":{"id":"mag:2188321475","doi":null,"is_oa":false,"landing_page_url":"https://www.esciencecentral.org/journals/novel-immunotherapy-to-eliminate-minimal-residual-disease-in-aml-patients-2329-8790.1000112..pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008824892","display_name":"Justin Paul Kline","orcid":"https://orcid.org/0000-0002-2967-6448","observed_orcids":["https://orcid.org/0000-0002-2967-6448"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Justin Kline","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2967-6448","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5008824892"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.7939000129699707,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.7939000129699707,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.19349999725818634,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9959999918937683},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.9950000047683716},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.8119999766349792},{"id":"https://openalex.org/keywords/wt1-peptide","display_name":"WT1 peptide","score":0.8199999928474426},{"id":"https://openalex.org/keywords/tlr3-agonist","display_name":"TLR3 agonist","score":0.9810000061988831},{"id":"https://openalex.org/keywords/immunoadjuvant","display_name":"immunoadjuvant","score":0.800000011920929},{"id":"https://openalex.org/keywords/treg-depletion","display_name":"Treg depletion","score":0.9169999957084656},{"id":"https://openalex.org/keywords/anti-cd25-antibody","display_name":"anti-CD25 antibody","score":0.9959999918937683},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.7239999771118164},{"id":"https://openalex.org/keywords/clinical-trials","display_name":"clinical trials","score":0.593999981880188}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.795595109462738},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.7498003244400024},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.6457349061965942},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6355067491531372},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5679817795753479},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.48328760266304016},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.4832375943660736},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4648958742618561},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.451702743768692},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.42875024676322937},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41739532351493835},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33872300386428833}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2188321475","doi":null,"is_oa":false,"landing_page_url":"https://www.esciencecentral.org/journals/novel-immunotherapy-to-eliminate-minimal-residual-disease-in-aml-patients-2329-8790.1000112..pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":51,"referenced_works":["https://openalex.org/W1967471460","https://openalex.org/W1973647796","https://openalex.org/W1987006648","https://openalex.org/W1992002083","https://openalex.org/W1992343552","https://openalex.org/W2000514038","https://openalex.org/W2001740313","https://openalex.org/W2008744764","https://openalex.org/W2010322940","https://openalex.org/W2027857664","https://openalex.org/W2029546284","https://openalex.org/W2031585195","https://openalex.org/W2033317985","https://openalex.org/W2033525557","https://openalex.org/W2034625094","https://openalex.org/W2040600740","https://openalex.org/W2053453932","https://openalex.org/W2053737749","https://openalex.org/W2060656939","https://openalex.org/W2073310925","https://openalex.org/W2090640877","https://openalex.org/W2090789725","https://openalex.org/W2093358784","https://openalex.org/W2100143031","https://openalex.org/W2101560723","https://openalex.org/W2106187671","https://openalex.org/W2110228704","https://openalex.org/W2111943649","https://openalex.org/W2113030185","https://openalex.org/W2113638010","https://openalex.org/W2114601875","https://openalex.org/W2118120713","https://openalex.org/W2125956827","https://openalex.org/W2127493600","https://openalex.org/W2137758676","https://openalex.org/W2138163780","https://openalex.org/W2139276258","https://openalex.org/W2141809833","https://openalex.org/W2144182715","https://openalex.org/W2148301776","https://openalex.org/W2148911309","https://openalex.org/W2151234463","https://openalex.org/W2152217218","https://openalex.org/W2152678202","https://openalex.org/W2154478576","https://openalex.org/W2156222101","https://openalex.org/W2161872048","https://openalex.org/W2168491130","https://openalex.org/W2193325565","https://openalex.org/W2333450059","https://openalex.org/W4252910285"],"related_works":["https://openalex.org/W2033317985","https://openalex.org/W2107200082","https://openalex.org/W7095417049","https://openalex.org/W2600469406","https://openalex.org/W2027857664","https://openalex.org/W3163829944","https://openalex.org/W2552695032","https://openalex.org/W2174867586","https://openalex.org/W1573832982","https://openalex.org/W4283027744"],"abstract_inverted_index":{"Even":[0],"with":[1,11,75,157,162],"the":[2,7,39,102,127,136,151],"most":[3],"sophisticated":[4],"chemotherapy":[5,55],"regimens,":[6],"majority":[8],"of":[9,32,104,110,138,150,153],"patients":[10,70,81,161],"acute":[12],"myeloid":[13],"leukemia":[14,45],"will":[15,99,124],"eventually":[16,88],"experience":[17],"a":[18,67],"relapse":[19,31],"and":[20,49,108],"die":[21],"from":[22],"their":[23],"disease.":[24],"New":[25],"treatments":[26,59],"are":[27,71],"needed":[28],"to":[29,43,53,117,134],"prevent":[30],"disease":[33,86,91],"in":[34,72,90,115,148,160],"these":[35,80],"patients.":[36],"Immunotherapy":[37],"using":[38,143],"host":[40],"immune":[41,106,112],"system":[42],"combat":[44],"represents":[46],"an":[47],"exciting":[48],"potentially":[50],"efficacious":[51],"addition":[52],"standard":[54],"for":[56],"AML.":[57],"Immune-base":[58],"may":[60],"be":[61],"particularly":[62],"effective":[63],"when":[64,69],"administered":[65],"at":[66],"time":[68],"clinical":[73,132],"remission":[74],"normal":[76],"blood":[77],"counts;":[78],"nevertheless,":[79],"often":[82],"have":[83],"minimal":[84],"residual":[85],"which":[87],"results":[89],"relapse.":[92],"Successful":[93],"vaccinationbased":[94],"immunotherapy":[95,142],"targeting":[96],"leukemia-specific":[97],"antigens":[98],"likely":[100],"require":[101],"administration":[103],"powerful":[105],"adjutants":[107],"removal":[109],"negative":[111],"regulatory":[113,155],"pathways":[114],"order":[116],"achieve":[118],"maximal":[119],"efficacy.":[120],"This":[121],"review":[122],"article":[123],"focus":[125],"on":[126],"rationales":[128],"underlying":[129],"our":[130],"ongoing":[131],"trial":[133],"test":[135],"efficacy":[137],"WT1":[139],"peptide":[140],"based":[141],"TLR3":[144],"agonist":[145],"as":[146],"adjuvant":[147],"combination":[149],"depletion":[152],"T":[154],"cells":[156],"anti-CD25":[158],"antibody":[159],"hematologic":[163],"malignancies.":[164]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-06-24T00:00:00"}